Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston May 30, 2020 1:01am
268 Views
Post# 31091135

RE:ATE

RE:ATE
jomby wrote: these are onto something big...severe pain is a pretty big market around the world.

https://www.globalive.com/media/powerful-pain-relief-daniel-legault-antibe-therapeutics/



Hi , thanks for your message ... having established one of the most liquid securities on the TSXV, we share your desire to see our US presence and trading volumes grow -- and we are methodically working towards this goal. Foremost, we see the upcoming release of Phase 2 top-line data as a key stepping stone on that path. Over several years, we have been investing in our US presence, including regular participation in US investor events, establishing and nurturing relationships with US brokers and institutions, and -- more recently -- evaluation of upper-tier IR firms (we have a smaller retail-focused IR firm on retainer right now). Moreover, as you know, we expressed our interest in listing on a more senior exchange two yrs ago, with a view to enabling a wider swath of US institutions and professional investors to hold our shares and, of course, to capture increased investor visibility overall. To that end, we have filed the documents needed to effect such a listing -- so we are ready to go when the timing is right. Our view is that end-of-Phase 2 results, enhanced IR effort, and our listing plans form the basis for long-term, sustainable growth in the profile, investor base and trading volumes that we all seek. , I hope this answers your question and provides some insight into our strategy -- we appreciate your interest and longstanding support.

Re: 's previous enquiry and Antibe's email response, is MARSdd.com one of the IR firms on Antive's payroll?


Bullboard Posts